Celyad SA Net Change in Intangible Assets 2014-2024 | CYAD

Celyad SA net change in intangible assets from 2014 to 2024. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.

Celyad SA Net Change in Intangible Assets 2014-2024 | CYAD

Celyad SA net change in intangible assets from 2014 to 2024. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$245.5B
Amgen (AMGN)$159.6B
Gilead Sciences (GILD)$146.9B
Vertex Pharmaceuticals (VRTX)$100.7B
Bristol Myers Squibb (BMY)$98.6B
CSL (CSLLY)$85.1B
GSK (GSK)$80.3B
Regeneron Pharmaceuticals (REGN)$61.5B
Alnylam Pharmaceuticals (ALNY)$58.8B
Argenex SE (ARGX)$40B
BioNTech SE (BNTX)$27.3B
Insmed (INSM)$27B
Royalty Pharma (RPRX)$20.4B
Biogen (BIIB)$20.3B
Incyte (INCY)$17B
Illumina (ILMN)$15.4B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15B
Ascendis Pharma (ASND)$12.1B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$11B
Moderna (MRNA)$10.9B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.6B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Halozyme Therapeutics (HALO)$7.9B